Meiji Yasuda Asset Management Co Ltd. Decreases Stock Holdings in IQVIA Holdings Inc. $IQV

Meiji Yasuda Asset Management Co Ltd. reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,468 shares of the medical research company’s stock after selling 320 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in IQVIA were worth $435,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Continuum Advisory LLC raised its stake in shares of IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company’s stock worth $354,000 after purchasing an additional 64 shares during the period. Ballentine Partners LLC increased its holdings in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock worth $260,000 after buying an additional 69 shares during the last quarter. Independent Advisor Alliance raised its position in IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after acquiring an additional 72 shares during the period. ST Germain D J Co. Inc. boosted its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Finally, Nemes Rush Group LLC grew its position in shares of IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 81 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Barclays lifted their price target on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Citigroup restated a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Mizuho increased their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Evercore ISI boosted their price objective on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Finally, Redburn Partners set a $214.00 price objective on shares of IQVIA in a report on Wednesday, September 3rd. Eighteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $229.64.

IQVIA Stock Performance

NYSE:IQV opened at $183.97 on Thursday. The business’s fifty day moving average is $181.41 and its 200 day moving average is $167.47. The firm has a market cap of $31.28 billion, a price-to-earnings ratio of 26.62, a PEG ratio of 2.08 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $248.03.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.